Candida Chorioamnionitis Leads to Preterm Birth and Adverse Fetal-Neonatal Outcome.

Candida chorioamnionitis is rare but can lead to neonatal infection, high mortality, and neurodevelopmental impairment. We aimed to investigate maternal clinical features and perinatal outcomes and discuss future management strategies. We reviewed the medical records of women with Candida chorioamnionitis at our hospital over a 10-year period (n = 9) and previous published case reports and case series. The most prevalent Candida species was C. albicans (71.3% of the all cases). The most prevalent predisposing condition was preterm premature rupture of membranes (31/123, 25.2%), followed by pregnancy with a retained intrauterine contraceptive device (26/123, 21.1%) and pregnancy after in vitro fertilization (25/123, 20.3%). Preterm labor was the most common symptom (52/123, 42.3%), and only 13% of cases involved fever. Of the infants, 27% of the singletons and 23.8% of the twins were born before 22 gestational weeks, while 60% of the singletons and 76.2% of the twins were born at 22-36 weeks. The median birth weight of the babies born after 22 weeks was 1230 g. The mortality rates of the singletons and twins born after 22 weeks of gestation in the year 2000 or later were 28.6% and 52.4%, respectively. Antenatal treatment for Candida chorioamnionitis has not been established.

1. Introduction

Despite the high incidence of vulvovaginal candidiasis during pregnancy (13–20%) [1, 2], Candida species rarely cause chorioamnionitis. A recent neonatal study demonstrated that chorioamnionitis is an important risk factor of invasive early-onset candidiasis in extremely low-birth-weight infants, which leads to high mortality (71%) and neurodevelopmental impairment rates (86%) [3]; thus, the establishment of antenatal management is crucial. Since the first case of chorioamnionitis caused by Candida albicans that resulted in preterm birth and neonatal death was reported in 1958 [4], many case reports and short case series have been published. However, owing to the rarity of the disease, only two studies involving small groups of patients, a case series of 32 patients [5] and a case control study of 18 patients [6], have been published to date. Therefore, the clinical features of Candida chorioamnionitis are not well understood and management of the disease has not been established yet. Here, we present a case series of Candida chorioamnionitis in the past 10 years at our hospital and review the previously published case reports and case series. This study aimed to investigate the maternal clinical features and perinatal outcomes of these cases and discuss future management strategies.

2. Materials and Methods

We reviewed the medical records of women with Candida chorioamnionitis who attended the University of Miyazaki Hospital, a tertiary medical center in Miyazaki, Japan, between 2007 and 2016. The ethics committee of the Faculty of Medicine of University of Miyazaki approved this study (registration number O-0135). Candida chorioamnionitis is diagnosed on the basis of one or more of the following criteria: (1) Candida species are isolated from amniotic fluid obtained using transabdominal amniocentesis; (2) clinical or histological chorioamnionitis along with fetal/neonatal/placental culture test results positive for Candida species; or (3) histological chorioamnionitis (defined by polymorphonuclear leukocytes in the chorion or chorioamnion) and/or funisitis (defined by polymorphonuclear leukocytes in the wall of a blood vessel in the umbilical cord or the chorionic plate) involving yeast forms with pseudohyphae on periodic acid-Schiff staining, which is characteristic of Candida species. Cases of neonatal congenital candidiasis without any signs of maternal clinical/histological chorioamnionitis were excluded owing to the possibility of a birth canal infection during delivery rather than an in utero infection. In our hospital, we routinely perform transabdominal amniocentesis in women with preterm labor with or without preterm premature rupture of membranes (pPROM) to exclude intra-amniotic infection after obtaining their informed consent, unless other comorbid conditions such as placental position, inadequate amniotic space, or large bag protrusion into the vagina are present since we have reported that management with amniocentesis for women with preterm labor with intact membranes might improve neonatal outcome born between 22 and 28 weeks of gestation [7]. Umbilical cord blood cultures were immediately collected after delivery from all the women with preterm delivery and from those with term delivery who had signs of clinical chorioamnionitis, such as fever, leukocytosis, and maternal/fetal tachycardia. Histopathological examinations of the placentas/umbilical cords from these women were also performed. Periodic acid-Schiff staining was additionally performed after hematoxylin and eosin staining when a Candida infection was suspected.

We searched Medline, PubMed, and Google Scholar for case reports and case series in the English literature that were published till December 2016, using the terms “chorioamnionitis,” “intra-amniotic infection,” “Candida species,” “Candida albicans,” “Candida glabrata,” “Torulopsis glabrata,” and “congenital candidiasis”. We also searched the references of the published case series. We used the above-mentioned criteria for Candida chorioamnionitis and excluded duplicate cases and reports without adequate information about the maternal clinical course.

3. Results

3.1. Case Series

Between January 2007 and December 2016, 2717 deliveries were performed in our hospital. During this period, we had nine cases (0.3%) of Candida chorioamnionitis (Table 1). The isolated organisms were C. albicans in six women, C. glabrata in two women, and C. famata in one woman. Eight cases were antenatally diagnosed using transabdominal amniocentesis. One case, in which a transabdominal amniocentesis was not conducted, was diagnosed as histological chorioamnionitis and funisitis with Candida infection using an umbilical blood culture. This case involved dichorionic diamniotic (Di-Di) twins, of whom only the first infant had C. albicans infection.

Table 1

Clinical features of nine cases of Candida chorioamnionitis in our hospital.

Case	Age (y)	GA at delivery	Species	Positive culture	Predisposing conditions	Clinical signs	BW (g)	CCC	Neonatal outcome
1	31	21 w 6 d	Candida albicans	Amniotic fluid	IVF	Preterm labor and afebrile  WBC: 16,500/mm3  CRP: 0.51 mg/dL	490	No	Artificial abortion
2	31	22 w 6 d	C. glabrata	Amniotic fluid	IVF	Preterm labor and afebrile  WBC: 11,600/mm3  CRP: 1.68 mg/dL	594	Yes	Death on day 59
3	28	23 w 0 d	C. famata	Amniotic fluid	Smoking	Preterm labor and afebrile  WBC: 16,400/mm3  CRP: 0.68 mg/dL	498	No	Hydrocephalus after IVH
4	35	23 w 3 d	C. albicans	Amniotic fluid	IVFGestational diabetes	Preterm labor and afebrile  WBC: 11,700/mm3  CRP: 3.71 mg/dL	580	Yes	Neonatal death
5	28	23 w 4 d	C. albicans	Amniotic fluid	Pregestational diabetes	Preterm labor and afebrile  WBC: 12,600/mm3  CRP: 3.8 mg/dL	536	No	Brain atrophy and CLD
6	33	25 w 2 d	C. albicans	Amniotic fluid	None	Preterm labor and afebrile  WBC: 15,400/mm3  CRP: 7.51 mg/dL	786	No	PDA ligation
7	26	26 w 6 d	C. albicans	Amniotic fluid	None	Preterm labor and afebrile  WBC: 9,800/mm3  CRP: 3.05 mg/dL	924	Yes	CLD
8	36	28 w 2 d	C. albicans	Umbilical blood	Di-Di twins	Preterm labor and afebrile  WBC: 9,500/mm3  CRP: 3.34 mg/dL	1,290/1,168	No	NormalOnly one twin hadthe infection
9	38	33 w 3 d	C. glabrata	Amniotic fluid	pPROM	Afebrile, WBC: 10,200/mm3  CRP: 2.68 mg/dL	1,912	No	Normal

GA, gestational age; BW, birth weight; CCC, congenital cutaneous candidiasis; IVF, in vitro fertilization; Di-Di twin, dichorionic diamniotic twin; WBC, white blood cell; CRP, C-reactive protein; IVH, intraventricular hemorrhage; CLD, chronic lung disease; PDA, patent ductus arteriosus; pPROM, preterm premature rupture of membranes.

3.1.1. Maternal Clinical Features

The mean maternal age was 32 years (range, 26–38 years). Three cases of pregnancy after in vitro fertilization (IVF) embryo transfer and one case of pPROM occurred. One woman had pregestational diabetes, and another had gestational diabetes; both conditions were well controlled. None of the patients had an intrauterine contraceptive device (IUCD) or a cervical cerclage. Eight patients were hospitalized for preterm labor. None of the patients were febrile. In three patients, the white blood cell counts reached >15,000/mm2 and the C-reactive protein (CRP) levels ranged from 0.51 to 7.51 mg/dL (mean, 3.1 mg/dL). One patient had an induced abortion at 21 weeks of gestation. In seven women diagnosed using transabdominal amniocentesis, delivery was immediately induced by oxytocin or performed via cesarean section after diagnosis. The woman with Di-Di twins who did not undergo transabdominal amniocentesis had a spontaneous delivery. No women received antenatal corticosteroids.

3.1.2. Fetal/Neonatal Outcome

The case of induced abortion was excluded from the analysis. The mean gestational age at delivery was 24.5 weeks (range, 22–33 weeks). The mean birth weight was 690 g (range, 498–1912 g). One of the twins, neither of whom had been diagnosed prenatally, had a positive umbilical blood culture, and the other three infants had cutaneous candidiasis. All the infants received intravenous fluconazole or micafungin and did not test positive in the following blood and surface cultures. Two infants died at the neonatal intensive care unit, one of liver hemorrhage and the other of intestinal perforation. Two infants were at risk of severe neurological impairment at the time of discharge.

3.2. Literature Review

We identified 123 cases (102 singletons [4, 8–76]/21 twins [49, 62, 69, 77–90]) with Candida chorioamnionitis, including our nine cases for whom adequate maternal clinical data were available.

3.2.1. Microbiological Characteristics

Cultural identification was conducted in 101 cases, while the remaining 22 cases were diagnosed using histopathological placenta/umbilical findings without cultural identification. The most prevalent species was C. albicans (71.3% [72/101]), followed by C. glabrata (21.7% [22/101]), C. tropicalis (3% [3/101]), C. lusitaniae (2% [2/101]), C. parapsilosis (2% [2/101]), C. famata (1% [1/101]), and C. kefyr (1% [1/101]; Table 2). Coinfection with C. albicans and C. parapsilosis was found in two cases [56, 83], one of which was a twin pregnancy. C. albicans was identified in one infant, while C. parapsilosis was identified in another [83].

Table 2

Species identified in the literature review excluding 22 unidentified cases (n = 101).

Species	n (%)
Candida albicans	72/101 (71.3)
C. albicans alone	70/101 (69.3)
Coinfection with C. parapsilosis	2/101 (2)
C. glabrata	22/101 (21.7)
C. tropicalis	3/101 (3)
C. lusitaniae	2/101 (2)
C. famata	1/101 (1)
C. kefyr	1/101 (1)

3.2.2. Maternal Clinical Features

The maternal clinical features are shown in Table 3. The median maternal age was 29 years (range, 16–47 years). Five patients had pregestational or gestational diabetes, and one patient received prednisolone for suspected immunological miscarriages. None of the patients had human immunodeficiency virus infection or other immunosuppressive diseases. The most prevalent predisposing condition was pPROM in 25.2% (31/123) of the patients, followed by pregnancy with a retained IUCD (21.1% [26/123]), pregnancy after IVF (20.3% [25/123]), a history of transabdominal amniocentesis during the current pregnancy (8.9% [11/123]), or cervical cerclage (6.5% [8/123]). Of the cases, 11.4% (14/123) had a history of treatment for vulvovaginal candidiasis during the current pregnancy. Preterm labor was the most common symptom (42.3% [52/123]), while only 13% (16/123) of the cases involved fever. Cervical dilatation without uterine contraction was found in 8.9% (11/123) of the cases, while 9.8% (12/123) had no symptoms. Laboratory data were unavailable in most of the reports. No cases of maternal death occurred.

Table 3

Maternal clinical features in the literature review.

	n (%)
Maternal age, years; median (range)	29 (16–47)
Singleton/twins	102/21
Predisposing condition
pPROM	31/123 (25.2)
IUCD	26/123 (21.1)
IVF	25/123 (20.3)
History of amniocentesis during current pregnancy	11/123 (8.9)
Cervical cerclage	8/123 (6.5)
Pregestational or gestational diabetes	5/123 (4.1)
History of treatment for vaginal candidiasis during current pregnancy	14/123 (11.4)
Symptoms
Preterm labor with intact membranes	52/123 (42.3)
Fever	16/123 (13)
Cervical dilatation	11/123 (8.9)
Abdominal pain	7/123 (5.7)
Vaginal bleeding	6/123 (4.9)
Reduced fetal movement	2/123 (1.6)
None	12/123 (9.8)

pPROM, preterm premature rupture of membranes; IUCD, intrauterine contraceptive device; IVF, in vitro fertilization.

3.2.3. Fetal/Neonatal Outcome

The distribution of the gestational ages at delivery is shown in Table 4. Two singletons were excluded because of missing information on gestational age. Birth before 22 weeks occurred in 27% (27/100) of the singletons and 23.8% (5/21) of the twins, while birth between 22 and 36 weeks occurred in 60% (60/100) of the singletons and 76.2% (16/21) of the twins. The distributions of the singletons and twin births were as follows: between 22 and 23 weeks, 11% (11/100) and 9.5% (2/21), respectively; between 24 and 27 weeks, 24% (24/100) and 19% (4/21), respectively. The median birth weight of the babies born after 22 weeks was 1,230 g (range, 425–4350 g).

Table 4

Gestational age at delivery in the literature review.

Gestational age (weeks)	Singletons (n = 100)	Twins (n = 21)
<22	27/100 (27%)	5/21 (23.8%)
22–36	60/100 (60%)	16/21 (76.2%)
22-23	11/100 (11%)	2/21 (9.5%)
24–27	23/100 (23%)	4/21 (19%)
28–31	13/100 (13%)	7/21 (33.3%)
32–36	13/100 (13%)	3/21 (14.3%)
≥37	13/100 (13%)	0/21 (0%)

2 singletons with unknown gestational age were excluded.

The mortality rates of the singletons and twins born after 22 weeks are shown in Figure 1. Since the description of the clinical features of the infants varied among the reports, we were unable to obtain sufficient data to evaluate the prevalence of congenital candidiasis caused by Candida chorioamnionitis. Therefore, we analyzed all infants associated with Candida chorioamnionitis. The mortality rate of the singletons born after 22 weeks since 2000 was 29%, while that of the twins was 50%. In five cases of twins, only one twin was associated with Candida chorioamnionitis, and another twin had no signs of chorioamnionitis or funisitis. These five infants without chorioamnionitis or funisitis were excluded from the analysis. The overall mortality rate of the singletons since the year 2000 improved to 28.6% from 40.4% before the year 2000. The overall mortality rate of the twins since 2000 was 52.4%, higher than that of the singletons.

Figure 1

Perinatal mortality rate of infants with Candida chorioamnionitis born after 22 weeks' gestation in the literature review. (a) Singletons born before 2000; (b) singletons born in 2000 or later; (c) twins born before 2000; (d) twins born in 2000 or later. Black bar: fetal death; gray bar: neonatal death; white bar: alive for the first 28 days of life. One infant died on day 59. One infant died on day 42. One twin of five twins without chorioamnionitis was excluded from analysis.

3.2.4. Antenatal Treatment

Antenatal treatment was conducted in 13 cases, including four of the twins (Table 5) [41, 44, 64, 71, 73–76, 81, 87–89]. All the cases were diagnosed using amniotic fluid culture obtained through transabdominal amniocentesis at a median gestational age of 22 weeks (range, 19–26 weeks). Fluconazole was the most prevalent agent used in six cases, followed by amphotericin B in five cases and ketoconazole and micafungin in one case each. The administration routes included oral, intravenous, vaginal, transabdominal intra-amniotic, and transcervical intra-amniotic. The prolongation period varied from 0 days to 8 weeks. Six of 13 cases with antenatal treatment succeeded in having alive infants.

Table 5

Antenatal treatment for Candida chorioamnionitis.

GA at diagnosis (weeks)	GA at delivery (weeks)	Species	Antifungal agent	Administration route	Fetal/neonatal outcomes	Reference
19	19	Candida albicans	Fluconazole	Intravenous	Stillbirth	[74]
19	21	C. albicans	Fluconazole	Oral	Stillbirth	[75]
21	22	C. albicans	Fluconazole	Oral	Stillbirth	[64]
21	27	C. albicans	Fluconazole	Transabdominal intra-amniotic, oral, and vaginal	Alive	[71]
23	31	C. albicans	Fluconazole	Transabdominal intra-amniotic, oral, and vaginal	Alive	[71]
26	29	C. glabrata	Fluconazole	Intravenous	Alive (PVL)/alive	[81]
18	23	C. glabrata	Amphotericin B	Intravenous	Stillbirth	[88]
21	24	C. glabrata	Amphotericin B	Intravenous	Stillbirth/stillbirth	[87]
24	24	C. glabrata	Amphotericin B	Intravenous	Died on day 42	[76]
24	28	C. glabrata	Amphotericin B	Intravenous	Alive/alive	[89]
27	29	C. albicans	Amphotericin B	Transcervical intra-amniotic	Alive	[44]
21	21	C. albicans	Ketoconazole	Not described	Stillbirth	[91]
26	28	C. glabrata	Micafungin	Intravenous	Alive	[41]

GA, gestational age; PVL, periventricular leukomalacia.

4. Discussion

4.1. Epidemiology

The prevalence of Candida chorioamnionitis at our institution was 0.3% of all pregnant women. This finding is consistent with the 0.5% prevalence reported in a previous study [6]. However, considering that both institutions are regional referral centers, we suspect that the true prevalence is less frequent than 0.3–0.5%.

4.2. Maternal Clinical Features

The presence of an IUCD during pregnancy, an established risk factor of intra-amniotic Candida infection [92, 93], showed a high incidence (21.1% [26/123]) in this review. Contaminated foreign body caused direct insemination of Candida species into the uterus. Some authors suspect that cervical cerclage, another foreign body during pregnancy, is also a risk factor [6, 91]. However, the most prevalent predisposing condition was pPROM, which leads to an ascending infection of Candida species colonized in the vagina. The incidence of Candida species in the amniotic fluid of patients with pPROM was reportedly 5% using polymerase chain reaction and 3.2% using culture-based methods [93], which are higher than those of patients with preterm labor with intact membranes (1.2% and 0.6%, resp.) [94]. However, whether cervical cerclage and pPROM are risk factors is unclear because cervical incompetence, which is the indication for cervical cerclage, and pPROM could result from chorioamnionitis. Case reports of chorioamnionitis with C. glabrata associated with IVF have been increasing recently. A recent review reported that 65% of cases of C. glabrata chorioamnionitis were associated with IVF [74]. Our study showed that 20.3% (25/123) of cases with Candida chorioamnionitis were associated with IVF and that C. glabrata, C. albicans, C. parapsilosis, C. kefyr, and C. famata were identified. Several steps of the IVF procedure can contaminate the fertilized embryo or introduce the pathogen into the uterine cavity, although the risk of chorioamnionitis after IVF has not been well studied yet [95]. A case report showed that the eradication of Candida species in the vagina led to the birth of a healthy infant after stillbirth due to Candida chorioamnionitis [85]. The insemination of Candida species colonized in the skin through transabdominal amniocentesis could be another risk factor, as two authors suspected that the amniocentesis procedure itself led to the Candida chorioamnionitis [26, 57]. Amniocentesis provides an early diagnosis and an opportunity for aggressive management, including antenatal treatment, as described later. Candida chorioamnionitis may manifest as preterm labor, pPROM, or cervical incompetence without fever, while 39% (48/123) of cases in this study were antenatally diagnosed using amniotic fluid culture obtained through transabdominal amniocentesis. A recent case report also showed that the collection of amniotic fluid sludge succeeded to detect C. albicans [96]. Thus, we recommend performing transabdominal amniocentesis under strict aseptic conditions in cases of preterm labor or pPROM.

Since the information of Candida colonization in vagina was missing in most cases of the literature review, we were unable to evaluate the effect of Candida colonization in vagina on Candida chorioamnionitis in this study. A recent study, which showed recurrent vaginal colonization with C. albicans in early pregnancy was a risk factor for preterm delivery and low birth weight, indicates that the routine screening and consequent treatment for Candida colonization can be useful to improve pregnancy outcomes [96]. Although it is still unknown that vaginal colonization with Candida is associated with Candia chorioamnionitis, we also suggest that the screening and treatment for Candida colonization in vagina in early pregnancy is a reasonable strategy to prevent ascending infection.

4.3. Fetal/Neonatal Outcome

Almost 30% of singletons and 50% of twins born after 22 weeks died, even after the year 2000. Immaturity and severe fetal inflammation could be causes of the high mortality rate. As shown in Table 4, among the singletons delivered after 22 weeks of gestation, almost half were born before 28 weeks.

4.4. Antenatal Treatment

Antenatal treatment for Candida chorioamnionitis is challenging. Although the maternal administration of various antifungal agents via various routes has been conducted, only half of cases resulted in the delivery of live infants. Fluconazole was the most popular agent used in seven cases. However, fluconazole has less activity against C. glabrata, the second most prevalent species, and whether fluconazole crosses the placenta is unknown [97]. The use of high-dose systemic fluconazole during the first trimester has the potential risk of teratogenic effects on the fetus [97, 98], although a cohort study showed that low-dose fluconazole was not associated with birth defect [99]. Thus, amphotericin B is recommended as the first-line treatment in cases of invasive candidiasis in pregnant women and neonatal candidiasis [98]. The advantages of amphotericin B include that it crosses the placenta, has no reported adverse effects in humans [97], and is generally effective against C. glabrata. One case report showed that intravenous amphotericin B treatment resulted in pregnancy extension by 4 weeks and the delivery of live infants with no signs of inflammatory changes in the placenta or umbilical cord [89], although three other cases resulted in stillbirth [76, 87, 88]. Micafungin was used in one case, although its efficacy and safety in pregnant women are unclear, and whether it crosses the placenta remains unknown. However, its high molecular weight (approximately 1292 for the sodium salt), low lipid solubility, and very high protein binding ability should limit its transfer to the fetus [97]. Some cases of successful treatment with intra-amniotic administration were also reported [49, 71]. Transcervical intra-amniotic amphotericin B administration succeeded in extending a pregnancy by 2 weeks and resulted in the delivery of a healthy infant [49]. Transabdominal intra-amniotic fluconazole treatment with oral and vaginal administration successfully extended pregnancy by 6–8 weeks and resulted in the delivery of live infants [71]. Sheep studies showed that intra-amniotic fluconazole treatment prevented systemic inflammation and cerebral inflammation and injury [100, 101]. These reports indicate that intra-amniotic treatment is an antenatal treatment to be considered. We suggest amphotericin B should be chosen as a first-line agent and fluconazole should be avoided due to the possibility of adverse outcomes for the fetus [97].

5. Conclusion

Candida chorioamnionitis may manifest as preterm labor, pPROM, or cervical incompetence without fever. Therefore, Candida chorioamnionitis should be considered in pregnant women with these symptoms, even in the absence of fever, especially in those with early gestation with a retained IUCD, pregnancy after IVF, a history of amniocentesis, or cervical cerclage and preterm delivery. The preterm birth and fetal/neonatal mortality rates are high, and antenatal treatment has yet to be established.